Rechercher un essai clinique
Autre(s) option(s) de recherche
36 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Essai terminé = 
; Financé par un membre IRDiRC = 
; Membre d'un ERN = 
Essai(s) clinique(s) national(aux)
ROYAUME-UNI
Tyne & Wear
NEWCASTLE-UPON-TYNE
EMPOWER: EMesis in Pregnancy - Ondansetron With mEtoclopRamide
Newcastle University
Newcastle Clinical Trials Unit
ALLEMAGNE
Berlin
ADDRESS: NOT PROVIDED - DE
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial - DE
Institution: Information not provided - DE
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STATIN: Étude contrôlée et randomisée visant à évaluer la pravastatine versus placebo pour la prévention de la prééclampsie - BE
CHU Brugmann
Service de médecine foetale / Fetal medicine department
BELGIQUE
VLAAMS BRABANT
LEUVEN
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial - BE
UZ Leuven - Campus Gasthuisberg
Dienst Gynaecologie en Verloskunde / Clinical Department of Obstetrics and Gynaecology
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial -ES
Institution: Information not provided - ES
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
Phase II Study of Nicotinamide in Early Onset Preeclampsia
Institution: Information not provided - US
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial - IT
Institution: Information not provided - IT
SUEDE
Region Stockholm
SOLNA
Effects of Nitrate-rich Beetroot Juice in Pregnant Women With High Blood Pressure - SE
Karolinska Institutet
Department of Physiology and Pharmacology (FYFA)
ESPAGNE
Comunidad Valenciana
VALENCIA
hSCU-PRP: Umbilical cord plasma for treating endometrial pathologies (thin endometrium / Ash erman's syndrome/ endometria atrophy)
Hospital Universitario y Politécnico La Fe
Servicio de Obstetricia y Ginecología
ROYAUME-UNI
Greater London
LONDON
MCRN007: An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome (phase II) - UK
University College London Hospitals, NHS Foundation Trust
Endocrinology Department
ALLEMAGNE
Baden-Württemberg
ULM
An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation -DE-
Zentrum für Seltene Erkrankungen am Universitätsklinikum Ulm
Zentrum für Seltene Erkrankungen (ZSE) ULM
ALLEMAGNE
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -DE
Institution: Information not provided - DE
BELGIQUE
OOST-VLAANDEREN
GENT
Essai d'extension à long terme portant sur la setmélanotide (RM-493) chez des patients ayant terminé un essai utilisant la setmélanotide dans le traitement de l'obésité liée à des défauts génétiques en amont du récepteur aux mélanocortines de type 4 (MC4R) dans la voie leptine-mélanocortine - BE
Ghent University Hospital - UZ Gent
Ghent University Hospital
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - CA
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome -ES
Institution: Information not provided - ES
ESPAGNE
Madrid
MADRID
A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to <6 years of age with Rare Genetic Causes of Obesity -ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
Institution: Information not provided - US
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Essai de phase 3, randomisé, en double aveugle, évaluant deux formulations de setmelanotide (quotidienne et hebdomadaire) suivi du setmelanotide hebdomadaire en ouvert chez les patients présentant des anomalies génétiques spécifiques de la voie du récepteur de la mélanocortine-4 et traités actuellement avec une dose stable de la formulation quotidienne -FR
Institution: Information not provided - FR
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Étude de phase 2 randomisée, en double aveugle, contrôlée par placebo, multicentrique, en deux parties, évaluant l'efficacité, l'innocuité et la tolérance du RGH-706 chez les patients atteints du syndrome de Prader-Willi -FR
Institution: Information not provided - FR
FRANCE
OCCITANIE
TOULOUSE
OXYJEUNE : Effets d'administrations intranasales d'ocytocine sur l'anxiété, les troubles du comportement et l'hyperphagie chez des enfants âgés de 3 à 12 ans présentant un syndrome de Prader-Willi (Phase III)
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi
FRANCE
OCCITANIE
TOULOUSE
Étude interventionnelle de suivi à long terme jusqu'à l'âge de 4 ans des enfants atteints du syndrome de Prader-Willi inclus dans l'essai clinique OTBB3 et comparaison avec une cohorte non traitée d'enfants atteints du syndrome de Prader-Willi. -FR
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome - IT
Institution: Information not provided - IT
PAYS-BAS
Zuid-Holland
ROTTERDAM
Dutch Growth Hormone Cohort study in children with Prader-Willi syndrome: Long-term effects on growth, body composition, activity level and psychosocial development
Stichting Kind en Groei
PAYS-BAS
Zuid-Holland
ROTTERDAM
N- acetylcysteine treatment for skin picking in children and young adults with PWS: a randomized, controlled, cross-over trial
Stichting Kind en Groei
ROYAUME-UNI
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - GB
ROYAUME-UNI
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -GB
Institution: Information not provided - GB
ROYAUME-UNI
Merseyside
LIVERPOOL
Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome
Fazakerley Hospital
University Hospital Aintree - Diabetes and Endocrinology
ROYAUME-UNI
West Midlands
BIRMINGHAM
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic
Essai(s) clinique(s) multinational(aux)
AUSTRALIE
Victoria
ADDRESS: NOT PROVIDED - AU
A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruritus. - TURRIFIC Protocol Version 8
Institution: Information not provided - AU
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
Effect of folic acid supplementation in pregnancy on preeclampsia - Folic Acid Clinical Trial (FACT)A randomized, double-blind, placebo-controlled, Phase III, international multi-centre study of 4.0 mg of Folic Acid supplementation in pregnancy for the prevention of preeclampsia - Folic Acid Clinical Trial (FACT)
Institution: Information not provided - CA
ROYAUME-UNI
Greater London
LONDON
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial.
King's College Hospital
Harris Birthright Research Centre for Fetal Medicine
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
Institution: Information not provided - US
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation.
Institution: Information not provided - US
HONGRIE
Dél-Dunántúl
ADDRESS: NOT PROVIDED - HU
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome.
Institution: Information not provided - HU
PAYS-BAS
Utrecht
ADDRESS: NOT PROVIDED - NL
Global Growth Hormone Study in Adults With Prader-Willi Syndroom
Institution: Information not provided - NL
ROYAUME-UNI
Greater London
LONDON